Home - Ventyx Biosciences DEVELOPING INNOVATIVE ORAL THERAPIES FOR AUTOIMMUNE, INFLAMMATORY, AND NEURODEGENERATIVE DISEASES We focus on autoimmune, inflammatory, and neurodegenerative diseases with high unmet need Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated […]
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides . . . SAN DIEGO, Jan 14, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today highlighted its 2025 pipeline strategy and provided
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a . . . SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc (Nasdaq: VTYX) (“Ventyx”, the “Company”), a clinical-stage biotech company developing oral therapies for autoimmune, inflammatory and neurodegenerative diseases, today announced positive top-line results from its Phase 2a study of VTX3232, a novel, CNS-penetrant NLRP3
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and . . . SAN DIEGO, Nov 07, 2024 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial . . . SAN DIEGO, Feb 27, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial
About Us - Ventyx Biosciences Developing novel medicines for autoimmune, inflammatory, and neurodegenerative diseases Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive […]
Ventyx Biosciences Reports First Quarter 2025 Financial Results and . . . SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported first quarter financial results and highlighted
Investors - Ventyx Biosciences Investors News We are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2 S1P1 receptor modulator for […]